Companies

Eli Lilly Buys 3 Vaccine Companies in $3.8 Billion Deal to Expand Infectious Disease Push

The drugmaker said the acquisitions target shingles, antibiotic-resistant bacteria, and Epstein-Barr virus.
Google LogoMark Us Preferred on Google
Eli Lilly Buys 3 Vaccine Companies in $3.8 Billion Deal to Expand Infectious Disease Push
An Eli Lilly pharmaceutical manufacturing plant at 50 ImClone Drive in Branchburg, New Jersey, on March 5, 2021. Mike Segar/Reuters
Evgenia Filimianova
|Updated:
0:00

Eli Lilly has announced agreements to acquire three vaccine-focused biotech companies in deals worth up to $3.83 billion, expanding the drugmaker’s infectious disease portfolio.

The company said on May 26 it will acquire Washington state-based Curevo, Swiss biotech LimmaTech Biologics, and Maryland-based Vaccine Company, with all three deals including an upfront payment and milestone payments.

Google LogoMark Us Preferred on Google
Evgenia Filimianova
Evgenia Filimianova
Author
Evgenia Filimianova is a UK-based journalist covering a wide range of international stories, with a particular interest in foreign policy, economy, and UK politics.